About Express Scripts (NASDAQ:ESRX)
Express Scripts, Inc. is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workersâ€™ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM). PBM segmentâ€™s services include retail network pharmacy management and retail drug card programs, home delivery services, specialty benefit services, patient care contact centers, benefit plan design and consultation, drug formulary management, compliance and therapy management programs, information reporting and analysis programs, rebate programs, and electronic claims processing and drug utilization review. EM segmentâ€™s services include distribution of pharmaceuticals and medical supplies to providers and clinics and healthcare account administration and implementation of consumer-directed healthcare solutions.
Industry, Sector and Symbol
Industry Health Care Plans
Sub-IndustryHealth Care Services
Trailing P/E Ratio10.46
Forward P/E Ratio10.19
Sales & Book Value
Annual Sales$100.29 billion
Price / Sales0.40
Cash Flow$10.04 per share
Price / Cash7.13
Book Value$26.34 per share
Price / Book2.72
Net Income$3.40 billion
Return on Equity25.46%
Return on Assets7.95%
Express Scripts (NASDAQ:ESRX) Frequently Asked Questions
What is Express Scripts' stock symbol?
Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."
How were Express Scripts' earnings last quarter?
Express Scripts Holding Company (NASDAQ:ESRX) posted its quarterly earnings results on Tuesday, October, 24th. The company reported $1.90 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $1.90. The firm had revenue of $24.68 billion for the quarter, compared to analyst estimates of $25.68 billion. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The company's quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.74 earnings per share. View Express Scripts' Earnings History.
When will Express Scripts make its next earnings announcement?
What guidance has Express Scripts issued on next quarter's earnings?
Express Scripts updated its fourth quarter earnings guidance on Tuesday, October, 24th. The company provided earnings per share (EPS) guidance of $2.03-2.11 for the period, compared to the Thomson Reuters consensus estimate of $2.04.
Where is Express Scripts' stock going? Where will Express Scripts' stock price be in 2017?
20 equities research analysts have issued twelve-month price objectives for Express Scripts' stock. Their forecasts range from $57.00 to $87.00. On average, they anticipate Express Scripts' share price to reach $75.08 in the next year. View Analyst Ratings for Express Scripts.
What are Wall Street analysts saying about Express Scripts stock?
Here are some recent quotes from research analysts about Express Scripts stock:
- 1. According to Zacks Investment Research, "We are upbeat about Express Scripts’ pharmacy-benefits management long-term outlook. The projection takes the volatile healthcare market trends, inflation, patent expiration and lower industry utilization growth into consideration. Furthermore, Express Scripts should benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. Branded drugs are becoming increasingly expensive due to double-digit brand inflation. Thus, continued rise in the price of specialty drugs and overwhelming regulatory burden is opening up considerable prospects for generics. However, over the past one year, Express Scripts has underperformed the broader industry in terms of price. Tough competition in the niche space and the persistent drug pricing issue are anticipated to affect the stock." (10/24/2017)
- 2. Jefferies Group LLC analysts commented, "We believe ESRX remains a Buy given our view that company fundamentals, including its FCF, are stable and that the stock's valuation is attractive at 9x FY18 P/E. That said, we recognize that headlines surrounding drug pricing pressure and the overhang from ESRX's Anthem contract will drive continued stock volatility NT." (2/17/2017)
Are investors shorting Express Scripts?
Express Scripts saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 30,738,576 shares, an increase of 1.3% from the November 15th total of 31,157,833 shares. Based on an average daily trading volume, of 3,982,136 shares, the days-to-cover ratio is presently 7.7 days. Currently, 5.4% of the company's shares are short sold.
Who are some of Express Scripts' key competitors?
Some companies that are related to Express Scripts include Biogen (BIIB), Anthem (ANTM), Stryker (SYK), Allergan (AGN), Shire (SHPG), Takeda Pharmaceutical (TKPYY), FRESENIUS SE&CO (FSNUY), Regeneron Pharmaceuticals (REGN), Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX), Humana (HUM), Baxter International (BAX), McKesson (MCK), Illumina (ILMN), Fresenius Medical Care (FMS), HCA (HCA), Actelion (ALIOF) and Essilor International (ESLOY).
Who owns Express Scripts stock?
Express Scripts' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Barrow Hanley Mewhinney & Strauss LLC (3.30%), Macquarie Group Ltd. (1.99%), Veritas Asset Management LLP (1.50%), Bank of New York Mellon Corp (1.35%), Nordea Investment Management AB (1.29%) and Dimensional Fund Advisors LP (1.16%). Company insiders that own Express Scripts stock include Christopher A Mcginnis, Everett Neville, Mahon Thomas P Mac, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.
Who sold Express Scripts stock? Who is selling Express Scripts stock?
Express Scripts' stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, Kensico Capital Management Corp, Bank of New York Mellon Corp, Old Mutual Global Investors UK Ltd., Barrow Hanley Mewhinney & Strauss LLC, Brown Advisory Inc., Macquarie Group Ltd. and Brandes Investment Partners LP. Company insiders that have sold Express Scripts company stock in the last year include Everett Neville, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.
Who bought Express Scripts stock? Who is buying Express Scripts stock?
Express Scripts' stock was purchased by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Pzena Investment Management LLC, Schwab Charles Investment Management Inc., Stifel Financial Corp, Veritas Asset Management LLP, Russell Investments Group Ltd., Prudential Financial Inc. and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Express Scripts.
How do I buy Express Scripts stock?
Shares of Express Scripts can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Express Scripts' stock price today?
One share of Express Scripts stock can currently be purchased for approximately $71.55.
How big of a company is Express Scripts?
Express Scripts has a market capitalization of $40.52 billion and generates $100.29 billion in revenue each year. The company earns $3.40 billion in net income (profit) each year or $6.07 on an earnings per share basis. Express Scripts employs 25,600 workers across the globe.
How can I contact Express Scripts?
Express Scripts' mailing address is ONE EXPRESS WAY, ST. LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]
MarketBeat Community Rating for Express Scripts (ESRX)MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Express Scripts (NASDAQ:ESRX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.24||2.09||2.18||2.21|
|Ratings Breakdown: ||3 Sell Rating(s)|
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|4 Sell Rating(s)|
12 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
12 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|3 Sell Rating(s)|
13 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$74.80||$70.46||$70.46||$75.24|
|Price Target Upside: ||4.54% upside||15.21% upside||12.16% upside||22.51% upside|
Express Scripts (NASDAQ:ESRX) Consensus Price Target History
Express Scripts (NASDAQ:ESRX) Analyst Ratings History
(Data available from 12/17/2015 forward)
Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart
Express Scripts (NASDAQ ESRX) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/24/2017||Q3 2017||$1.90||$1.90||$25.68 billion||$24.68 billion||View||N/A|
|7/25/2017||Q2 2017||$1.71||$1.73||$25.52 billion||$25.35 billion||View||N/A|
|4/24/2017||Q1 17||$1.32||$1.33||$24.95 billion||$24.65 billion||View||N/A|
|2/14/2017||Q4 2016||$1.87||$1.88||$26.31 billion||$24.90 billion||View||Listen|
|10/25/2016||Q3||$1.74||$1.74||$25.48 billion||$25.41 billion||View||Listen|
|7/25/2016||Q216||$1.57||$1.57||$25.42 billion||$25.20 billion||View||Listen|
|4/25/2016||Q1||$1.22||$1.22||$25.20 billion||$24.80 billion||View||Listen|
|2/16/2016||Q4||$1.56||$1.56||$26.58 billion||$26.18 billion||View||Listen|
|10/27/2015||Q315||$1.44||$1.45||$26.38 million||$25.22 million||View||Listen|
|7/28/2015||Q215||$1.40||$1.44||$26.13 billion||$25.45 billion||View||Listen|
|4/28/2015||Q115||$1.10||$1.10||$24.34 billion||$24.90 billion||View||Listen|
|2/23/2015||Q414||$1.38||$1.39||$25.68 billion||$26.31 billion||View||Listen|
|10/28/2014||Q314||$1.29||$1.29||$24.93 billion||$25.78 billion||View||Listen|
|7/29/2014||Q214||$1.22||$1.23||$24.42 billion||$25.11 billion||View||Listen|
|4/29/2014||Q114||$1.01||$0.99||$23.81 billion||$23.69 billion||View||Listen|
|2/20/2014||Q413||$1.12||$1.12||$25.49 billion||$25.78 billion||View||N/A|
|10/25/2013||Q313||$1.08||$1.08||$25.01 billion||$25.92 billion||View||Listen|
|7/29/2013||Q2 2013||$1.10||$1.12||$25.51 billion||$26.40 billion||View||Listen|
|4/29/2013||Q1 2013||$0.97||$0.99||$25.55 billion||$26.06 billion||View||Listen|
|2/18/2013||Q4 2012||$1.04||$1.05||$27.24 billion||$27.41 billion||View||Listen|
|11/5/2012||Q312||$0.99||$1.02||$27.48 billion||$27.00 billion||View||N/A|
Express Scripts (NASDAQ:ESRX) Earnings Estimates
2017 EPS Consensus Estimate: $7.01
2018 EPS Consensus Estimate: $7.73
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Express Scripts (NASDAQ:ESRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.68%
Institutional Ownership Percentage: 88.44%
Express Scripts (NASDAQ ESRX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/1/2017||Phyllis S. Anderson||VP||Sell||643||$62.37||$40,103.91|| |
|10/31/2017||Timothy C Wentworth||CEO||Buy||8,000||$61.13||$489,040.00|| |
|9/11/2017||Woodrow A Myers Jr||Director||Sell||3,900||$63.93||$249,327.00|| |
|9/8/2017||Phyllis S Anderson||VP||Sell||578||$63.13||$36,489.14|| |
|8/23/2017||Everett Neville||VP||Sell||1,163||$61.48||$71,501.24|| |
|5/19/2017||Phyllis S Anderson||VP||Sell||1,100||$60.08||$66,088.00|| |
|3/1/2017||Everett Neville||SVP||Sell||2,352||$70.16||$165,016.32|| |
|1/3/2017||Everett Neville||VP||Sell||1,123||$69.41||$77,947.43|| |
|9/14/2016||Woodrow A Myers Jr||Director||Sell||12,036||$70.40||$847,334.40|| |
|9/12/2016||Christopher A Mcginnis||VP||Sell||1,785||$70.77||$126,324.45|| |
|5/10/2016||Everett Neville||VP||Sell||800||$74.11||$59,288.00|| |
|4/29/2016||Mahon Thomas P Mac||Director||Sell||5,482||$73.93||$405,284.26|| |
|3/10/2016||Christopher A Mcginnis||VP||Sell||579||$68.56||$39,696.24|| |
|3/7/2016||Phyllis S Anderson||VP||Sell||614||$71.14||$43,679.96|| |
|2/29/2016||Everett Neville||VP||Sell||4,323||$71.00||$306,933.00|| |
|6/9/2015||Gary Wimberly||VP||Sell||1,644||$87.14||$143,258.16|| |
|6/1/2015||Gary Wimberly||VP||Sell||46,069||$86.15||$3,968,844.35|| |
|3/2/2015||Glen D Stettin||VP||Sell||2,674||$84.39||$225,658.86|| |
|2/25/2015||Glen D Stettin||VP||Sell||27,603||$87.55||$2,416,642.65|| |
|12/2/2014||Keith J Ebling||VP||Sell||10,000||$84.25||$842,500.00|| |
|12/1/2014||Steven B Miller||VP||Sell||4,896||$83.57||$409,158.72|| |
|11/28/2014||Glen D Stettin||VP||Sell||10,800||$82.96||$895,968.00|| |
|11/17/2014||John O Parker||Director||Sell||25,822||$78.75||$2,033,482.50|| |
|11/7/2014||Maura C Breen||Director||Sell||13,128||$77.80||$1,021,358.40|| |
|9/5/2014||Edward B Ignaczak||EVP||Sell||9,886||$75.28||$744,218.08|| |
|8/28/2014||Seymour Sternberg||Director||Sell||15,508||$74.12||$1,149,452.96|| |
|8/25/2014||Keith J Ebling||VP||Sell||10,000||$75.50||$755,000.00|| |
|8/5/2014||Gary G Benanav||Director||Sell||12,694||$70.82||$898,989.08|| |
|8/5/2014||Sara E Wade||VP||Sell||20,000||$70.44||$1,408,800.00|| |
|8/4/2014||David A Norton||VP||Sell||1,276||$71.02||$90,621.52|| |
|8/1/2014||Maura C Breen||Director||Sell||12,694||$69.94||$887,818.36|| |
|6/13/2014||George Paz||CEO||Sell||681,508||$71.21||$48,530,184.68|| |
|3/11/2014||Keith Ebling||VP||Sell||25,721||$78.69||$2,023,985.49|| |
|3/10/2014||Patrick Mcnamee||COO||Sell||68,425||$78.28||$5,356,309.00|| |
|3/10/2014||Steven Miller||VP||Sell||12,664||$77.96||$987,285.44|| |
|3/7/2014||Keith Ebling||VP||Sell||295,367||$77.29||$22,828,915.43|| |
|1/9/2014||Nicholas Lahowchic||Director||Sell||7,650||$72.00||$550,800.00|| |
|12/26/2013||Nicholas Lahowchic||Director||Sell||12,694||$70.00||$888,580.00|| |
|11/5/2013||Mahon Thomas Mac||Director||Sell||10,251||$63.20||$647,863.20|| |
|9/9/2013||Maura C Breen||Director||Sell||10,527||$64.12||$674,991.24|| |
|9/4/2013||Woodrow Myers, Jr.||Director||Sell||7,128||$64.66||$460,896.48|| |
|7/19/2013||Nicholas Lahowchic||Director||Sell||20,377||$66.26||$1,350,180.02|| |
|6/11/2013||Woodrow A Myers Jr||Director||Sell||1,750||$62.57||$109,497.50|| |
|5/28/2013||Woodrow A Myers Jr||Director||Sell||2,000||$63.75||$127,500.00|| |
|5/15/2013||Jeffrey Hall||CFO||Sell||13,307||$61.13||$813,456.91|| |
|5/8/2013||Woodrow A Myers Jr||Director||Sell||13,462||$61.22||$824,143.64|| |
|5/1/2013||Keith J Ebling||EVP||Sell||59,494||$59.58||$3,544,652.52|| |
|4/30/2013||Patrick Mcnamee||COO||Sell||271,972||$59.65||$16,223,129.80|| |
|3/14/2013||Mahon Thomas P Mac||Director||Buy||5,000||$59.58||$297,900.00|| |
|9/4/2012||Jeffrey Hall||CFO||Sell||75,000||$62.81||$4,710,750.00|| |
|8/8/2012||Edward B Ignaczak||EVP||Sell||115,466||$59.33||$6,850,597.78|| |
Express Scripts (NASDAQ ESRX) News Headlines
Express Scripts (NASDAQ:ESRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement
Express Scripts (NASDAQ ESRX) Stock Chart for Sunday, December, 17, 2017